联合光动力疗法和贝伐单抗治疗弓形虫相关性脉络膜新生血管。
Combination photodynamic therapy and bevacizumab for choroidal neovascularization associated with toxoplasmosis.
机构信息
Shri Bhagwan Mahavir Vitreoretinal Services, Sankara Nethralaya, Tamil Nadu, India.
出版信息
Indian J Ophthalmol. 2011 Jan-Feb;59(1):62-4. doi: 10.4103/0301-4738.73728.
Abstract
A 14-year-old girl presenting with visual loss in both eyes was diagnosed to have healed toxoplasma retinochoroiditis in the right eye with active choroidal neovascularization (CNV) secondary to toxoplasmosis in the left. She underwent combination photodynamic therapy (PDT) and intravitreal bevacizumab as primary treatment. PDT was performed as per the 'Treatment of Age-related Macular Degeneration by Photodynamic therapy' study protocol and was followed by intravitreal bevacizumab after 2 days. CNV regressed at 8 weeks of follow-up and remained stable at 8 months of follow-up. The initial visual acuity improved from 20/120 to 20/30. Combination therapy with PDT and intravitreal bevacizumab appears to be effective in the treatment of CNV secondary to toxoplasma retinochoroiditis.
摘要
一位 14 岁女孩因双眼视力丧失就诊，被诊断为右眼弓形虫性视网膜炎已愈合，左眼活动性脉络膜新生血管（CNV）继发于弓形虫病。她接受了联合光动力疗法（PDT）和玻璃体内贝伐单抗治疗作为一线治疗。PDT 按照“光动力疗法治疗年龄相关性黄斑变性”研究方案进行，随后在 2 天后进行玻璃体内贝伐单抗治疗。CNV 在 8 周的随访中消退，在 8 个月的随访中保持稳定。最初的视力从 20/120 提高到 20/30。PDT 和玻璃体内贝伐单抗联合治疗似乎对弓形虫性视网膜炎继发的 CNV 有效。
相似文献
1
Combination photodynamic therapy and bevacizumab for choroidal neovascularization associated with toxoplasmosis.
Indian J Ophthalmol. 2011 Jan-Feb;59(1):62-4. doi: 10.4103/0301-4738.73728.
2
Intravitreal bevacizumab for choroidal neovascularization in toxoplasmosis.
Acta Ophthalmol. 2009 Sep;87(6):688-90. doi: 10.1111/j.1755-3768.2008.01319.x. Epub 2008 Jul 8.
3
Bevacizumab vs photodynamic therapy for choroidal neovascularization in multifocal choroiditis.
Arch Ophthalmol. 2010 Sep;128(9):1100-3. doi: 10.1001/archophthalmol.2010.205.
4
Pattern electroretinographic results after photodynamic therapy alone and photodynamic therapy in combination with intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration.
Doc Ophthalmol. 2009 Aug;119(1):37-42. doi: 10.1007/s10633-009-9167-8. Epub 2009 Feb 19.
5
Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration.
Retina. 2008 May;28(5):675-81. doi: 10.1097/IAE.0b013e31816b316e.
6
Intravitreal bevacizumab for treatment of choroidal neovascularization secondary to toxoplasmic retinochoroiditis: a case series.
Semin Ophthalmol. 2015 May;30(3):181-7. doi: 10.3109/08820538.2013.838278. Epub 2013 Oct 31.
7
Photodynamic therapy for choroidal neovascularization in young adult patients.
Int Ophthalmol. 2010 Aug;30(4):345-51. doi: 10.1007/s10792-010-9346-3. Epub 2010 Feb 2.
8
Intravitreal bevacizumab alone versus combined verteporfin photodynamic therapy and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration: visual acuity after 1 year of follow-up.
Retina. 2010 Apr;30(4):548-54. doi: 10.1097/IAE.0b013e3181bcf1b8.
9
Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study).
Graefes Arch Clin Exp Ophthalmol. 2007 Sep;245(9):1273-80. doi: 10.1007/s00417-007-0557-x. Epub 2007 Feb 28.
10
Intravitreal bevacizumab (Avastin) as primary and rescue treatment for choroidal neovascularization secondary to ocular toxoplasmosis.
Int Ophthalmol. 2008 Aug;28(4):311-6. doi: 10.1007/s10792-008-9218-2. Epub 2008 Apr 10.
引用本文的文献
1
Clinical outcomes of intravitreal treatment for ocular toxoplasmosis: systematic review and meta-analysis.
Rev Soc Bras Med Trop. 2023 May 22;56:e05522022. doi: 10.1590/0037-8682-0552-2022. eCollection 2023.
2
Choroidal neo-vascular membrane in a paediatric optic disc pit: A case report.
Am J Ophthalmol Case Rep. 2022 Nov 12;28:101751. doi: 10.1016/j.ajoc.2022.101751. eCollection 2022 Dec.
3
Choroidal neovascularization in 111 eyes of children and adolescents.
Int Ophthalmol. 2022 Jan;42(1):157-166. doi: 10.1007/s10792-021-02018-2. Epub 2021 Aug 23.
4
Toxoplasma Retinochoroiditis with Chorioretinal Neovascularization in a Young Patient.
Case Rep Ophthalmol. 2021 Apr 16;12(1):259-263. doi: 10.1159/000512286. eCollection 2021 Jan-Apr.
5
An update on inflammatory choroidal neovascularization: epidemiology, multimodal imaging, and management.
J Ophthalmic Inflamm Infect. 2018 Sep 12;8(1):13. doi: 10.1186/s12348-018-0155-6.
6
Intravitreal aflibercept for choroidal neovascularization associated with chorioretinitis: a pilot study.
Clin Ophthalmol. 2017 Jul 20;11:1315-1320. doi: 10.2147/OPTH.S132923. eCollection 2017.
7
Inflammatory choroidal neovascularization in Indian eyes: Etiology, clinical features, and outcomes to anti-vascular endothelial growth factor.
Indian J Ophthalmol. 2017 Apr;65(4):295-300. doi: 10.4103/ijo.IJO_262_16.
8
Coexisting choroidal neovascularization and active retinochoroiditis-an uncommon presentation of ocular toxoplasmosis.
J Ophthalmic Inflamm Infect. 2015 Jul 12;5:22. doi: 10.1186/s12348-015-0051-2. eCollection 2015.
9
Choroidal neovascularization in 36 eyes of children and adolescents.
Eye (Lond). 2013 Oct;27(10):1158-68. doi: 10.1038/eye.2013.155. Epub 2013 Jul 26.
10
Photodynamic therapy combined with intravitreal bevacizumab in a patient with choroidal neovascularization secondary to choroidal osteoma.
Korean J Ophthalmol. 2012 Dec;26(6):478-80. doi: 10.3341/kjo.2012.26.6.478. Epub 2012 Nov 12.
本文引用的文献
1
Intravitreal bevacizumab (Avastin) as primary and rescue treatment for choroidal neovascularization secondary to ocular toxoplasmosis.
Int Ophthalmol. 2008 Aug;28(4):311-6. doi: 10.1007/s10792-008-9218-2. Epub 2008 Apr 10.
2
Choroidal neovascularisation in children.
Br J Ophthalmol. 2008 Apr;92(4):451-4. doi: 10.1136/bjo.2007.124586.
3
Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration.
Retina. 2006 Nov-Dec;26(9):988-93. doi: 10.1097/01.iae.0000247164.70376.91.
4
Verteporfin photodynamic therapy for choroidal neovascularization associated with toxoplasmic retinochoroiditis.
Retina. 2006 Apr;26(4):396-403. doi: 10.1097/01.iae.0000238552.76412.ae.
5
Clinical features and prognosis in ocular toxoplasmosis.
Jpn J Ophthalmol. 2004 Jul-Aug;48(4):386-91. doi: 10.1007/s10384-003-0069-0.
6
Visual outcome after surgical removal of choroidal neovascularization in pediatric patients.
Arch Ophthalmol. 2000 Oct;118(10):1373-8. doi: 10.1001/archopht.118.10.1373.
7
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.
Arch Ophthalmol. 1999 Oct;117(10):1329-45.
8
The surgical removal of subfoveal choroidal neovascularization. Ingrowth site as a predictor of visual outcome.
Retina. 1996;16(3):190-5. doi: 10.1097/00006982-199616030-00002.
9
Subretinal neovascularization in children and adolescents.
J Pediatr Ophthalmol Strabismus. 1995 May-Jun;32(3):178-82. doi: 10.3928/0191-3913-19950501-11.
10
Subretinal neovascularization in chronic uveitis.
Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1980;215(1):43-51. doi: 10.1007/BF00413395.
Zotero 插件